Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivastigmine for Apathy in Parkinson's Disease (CHoPA-I)
NCT00767091Phase 3Completed
- Sponsor
- CHU de Lille
- Start
- Mar 2009
- Primary completion
- Dec 2011
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of rivastigmine in apathy, sponsored by CHU de Lille. Started Mar 2009; status: completed.
02
Drugs
rivastigmine
03
Conditions
apathy
Beyond the preview
Go deeper on NCT00767091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00767091.